Distinct expression profiles of p63 variants during urothelial development and bladder cancer progression - Wikidata - awgldk - TriplyDB

Distinct expression profiles of p63 variants during urothelial development and bladder cancer progression

Distinct expression profiles of p63 variants during urothelial development and bladder cancer progression

http://www.wikidata.org/entity/Q34755858

about

Normal and neoplastic urothelial stem cells: getting to the root of the problem The microRNA feedback regulation of p63 in cancer progression Characterization of desmoglein expression in the normal prostatic gland. Desmoglein 2 is an independent prognostic factor for aggressive prostate cancer A place for precision medicine in bladder cancer: targeting the FGFRs.Dynamic Change in p63 Protein Expression during Implantation of Urothelial Cancer Clusters.Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy Gene and isoform expression signatures associated with tumor stage in kidney renal clear cell carcinoma Heterarchy of transcription factors driving basal and luminal cell phenotypes in human urothelium.p40 (ΔNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma.p63 expression defines a lethal subset of muscle-invasive bladder cancers.p63 steps into the limelight: crucial roles in the suppression of tumorigenesis and metastasis ΔNp63 promotes stem cell activity in mammary gland development and basal-like breast cancer by enhancing Fzd7 expression and Wnt signalling.Biomarkers for bladder cancer management: present and future.Canonical Notch signalling is inactive in urothelial carcinoma.A common MicroRNA signature consisting of miR-133a, miR-139-3p, and miR-142-3p clusters bladder carcinoma in situ with normal umbrella cells Novel neoadjuvant therapy paradigms for bladder cancer: results from the National Cancer Center Institute Forum.Cytokeratin 15 marks basal epithelia in developing ureters and is upregulated in a subset of urothelial cell carcinomas.A cell of origin gene signature indicates human bladder cancer has distinct cellular progenitors.The effect of manipulation of silk scaffold fabrication parameters on matrix performance in a murine model of bladder augmentation.p63 is a suppressor of tumorigenesis and metastasis interacting with mutant p53.Modelling bladder cancer in mice: opportunities and challenges.p53 Family: Role of Protein Isoforms in Human Cancer.14-3-3σ and p63 play opposing roles in epidermal tumorigenesis.Loss of FOXA1 Drives Sexually Dimorphic Changes in Urothelial Differentiation and Is an Independent Predictor of Poor Prognosis in Bladder Cancer.Three differentiation states risk-stratify bladder cancer into distinct subtypes ΔNp63/DGCR8-Dependent MicroRNAs Mediate Therapeutic Efficacy of HDAC Inhibitors in Cancer.The p63 protein isoform ΔNp63α inhibits epithelial-mesenchymal transition in human bladder cancer cells: role of MIR-205.p63-expressing cells are the stem cells of developing prostate, bladder, and colorectal epithelia.Upregulation of cell adhesion through delta Np63 silencing in human 5637 bladder cancer cells.FOXA1, GATA3 and PPARɣ Cooperate to Drive Luminal Subtype in Bladder Cancer: A Molecular Analysis of Established Human Cell Lines.p63 expression correlates with sensitivity to the Eg5 inhibitor ZD4877 in bladder cancer cells.When urothelial differentiation pathways go wrong: implications for bladder cancer development and progression.Urothelial cancers: using biology to improve outcomes.Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer.Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity.Tp53 and its potential therapeutic role as a target in bladder cancer.Uroplakin 1b is critical in urinary tract development and urothelial differentiation and homeostasis.A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, an TERT promoter mutation status in sarcomatoid urothelial carcinomas of the upper urinary tract.On a FOX hunt: functions of FOX transcriptional regulators in bladder cancer.

P2860

Q26825948-41C7A0FC-569F-4A81-8ABA-9C2442F21CBE Q28084646-72A1EE1F-AB6E-4D91-9FD7-5AC81EAF13C8 Q28539356-7424B4FC-8203-45D8-B52F-0D683E0C16B8 Q30249143-0D02BD9E-C9B5-4B8A-9129-7B658F32E2AA Q30403508-582F6A0A-E4D1-4B8C-8D0B-0A6C3408588C Q33572016-3359CF02-9943-4BB0-95FE-00440B7B9CD1 Q33641747-0663C580-CC5A-44FD-9E95-4063EE325247 Q33652158-B7F351A2-D30D-4097-AA02-88994F1081A1 Q34067972-8CD197EA-2F9C-4449-8E38-D210578E915A Q34131185-B579A11A-90C3-4C9E-BDAF-53842BCAB276 Q34273826-E868E45A-AC09-440D-B503-61F673DC16EE Q34283057-45B3D5E0-08E2-4EB8-A244-788C8B50985D Q34448168-5B0D2F75-D66F-485D-864F-6506F6239DA5 Q34565523-50BF9578-BCBD-4E97-A0DC-B2586D8E1C2A Q34587506-CFCD7496-8352-49A1-812D-AD5C1C0D5D21 Q34670535-752C7C9C-7F26-4225-A8AC-07C770522E27 Q35049486-EFFFE986-3B76-4A1F-A72D-0A9BE2F1F1C1 Q35072270-BA840419-2D26-4EE9-B926-7B02DC376756 Q35165266-9CE44813-2C54-48D1-BCB3-C2CD51D645A8 Q35227440-1C7B0AE2-D14A-491B-BE26-E0D3D841764F Q35285703-826C9870-2012-4A37-8206-1393ABDB7B15 Q35326348-CF19948C-0801-431F-A1EA-51C88401F73F Q35562900-3964BADA-2BBA-41DC-AADD-6BA7CC07FE8A Q35568071-22C6E657-E508-4B5C-A7A5-37F1A6DAC647 Q35750975-F6351B7B-DA6C-4F16-863B-B6ECA94B58E1 Q36051831-5F6CF157-EE49-4BD3-A88D-A7F0AFFB712F Q36579525-9FED3ADD-8C3C-415B-9970-43D40EC0DD12 Q36855105-7930BD87-F698-4A24-BC57-EFA111AA35B1 Q37074167-F39E61CC-4C29-49DB-A156-1D8474656BBD Q37479778-1B74A029-9629-49EF-83BD-E141C81898C9 Q37644499-5916E3D9-9BA0-404B-812D-647A52616296 Q37933675-E427DA6A-04BC-4D1C-96E9-C2FF551E254F Q37965638-BEB7AB3C-402D-496E-BB07-97768088A47C Q38222834-779029A6-61C9-4D5F-B288-8DAE49613A81 Q38297729-5AD32B5B-6E0C-4D91-985F-950831F21737 Q38436074-15855AC4-F170-46CB-8E9F-4ECE7020665C Q38541294-F106818D-474A-40CF-B951-63EDE4E95DEC Q38732403-CDC9EED5-D6F5-4F96-925C-3545879E9D2B Q38774845-BFF23037-A47A-4CF0-AD00-289E9EAA3100 Q38789453-5483BFA8-1170-497A-8153-9838DFF6D314

P2860

Distinct expression profiles of p63 variants during urothelial development and bladder cancer progression

http://www.wikidata.org/entity/Q34755858

description

2011 nî lūn-bûn

@nan

2011 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մարտին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Distinct expression profiles o ...... and bladder cancer progression

@ast

Distinct expression profiles o ...... and bladder cancer progression

@en

Distinct expression profiles o ...... and bladder cancer progression

@nl

type

label

Distinct expression profiles o ...... and bladder cancer progression

@ast

Distinct expression profiles o ...... and bladder cancer progression

@en

Distinct expression profiles o ...... and bladder cancer progression

@nl

prefLabel

Distinct expression profiles o ...... and bladder cancer progression

@ast

Distinct expression profiles o ...... and bladder cancer progression

@en

Distinct expression profiles o ...... and bladder cancer progression

@nl

P1433

Q34755858-F35CA1BF-59E4-4D6B-BD32-8554745173AF

P1476

Q34755858-0B722EE7-8B7F-4D67-8F77-BF038DF5FA65

P2093

Q34755858-0A2950E7-DB1E-40E4-8D45-07B98926D163

Q34755858-4FE77036-D049-4FBC-8CB0-AE59974BEE4A

Q34755858-59151C95-21C9-4CC8-A13C-28806DADB69B

Q34755858-5FBD2DCA-DF9E-400E-B58B-B6ACFBA7FC60

Q34755858-81B7A1E9-D615-4ED6-B840-9C75A2EAE581

Q34755858-83335B19-F10F-4867-953F-85956AE90FF5

Q34755858-9463CF07-4385-44F2-A770-1025AA203E71

Q34755858-AFA41A66-9130-49F7-A6DC-7DA60E568774

Q34755858-F1C0F5BD-AAD6-48A3-BA50-FAA1F96F7498

P2860

Q34755858-0C0B20C1-A0E3-4313-AE5B-CA593A6D16A1

Q34755858-1322CAEE-0FE0-4E67-8FBE-CF3644D17182

Q34755858-159E93FD-F5F5-4CB2-AF7C-D6B5B5F8C0A5

Q34755858-16BBB8F0-F88E-424D-A1C2-A798D4491DCD

Q34755858-17A0F0EB-C138-4CF5-B0C5-E9D3FF222EF5

Q34755858-20B44C23-1576-4485-A515-1182D00F73EC

Q34755858-23168ACF-0786-45A7-AE23-9FAF1B1B5383

Q34755858-2A861E76-1AB9-48B5-8964-47E1C799F091

Q34755858-30E4DDC5-0AB5-4732-9D62-D3854593B925

Q34755858-3577E1D7-D0CE-4A02-8A00-CEB99D8A1471

P304

Q34755858-D875CB36-8EFC-409D-840D-490503A78B89

P31

Q34755858-BA70F48E-1B55-4145-989F-DF51DE08F233

P356

Q34755858-EA4E52BE-3342-4428-819F-2DF99F601518

P407

Q34755858-7C7F8AF4-C79F-4B15-A856-1DCC6DC598E7

P433

Q34755858-C53DABFB-9EC8-482E-ABE2-7848B0C45199

P478

Q34755858-AFE99602-DB96-407F-815F-8B454FF11C65

P50

Q34755858-699C40B6-A5FC-4F29-81A1-76E4A4931F55

P577

Q34755858-2193189E-3590-4C60-806F-F3BCA4AE0455

P5875

Q34755858-6B464698-1286-4E2C-BB67-4D361A71065C

P698

Q34755858-1C0B0559-4A0D-40A2-BCFB-B6DED74237B2

P932

Q34755858-FC038D96-1205-4DB8-883A-2FA1524385BD

P356

J.AJPATH.2010.11.061

P1433

The American Journal of Pathology

P1476

Distinct expression profiles o ...... and bladder cancer progression

@en

P2093

Carol Prives

http://www.w3.org/2001/XMLSchema#string

Josep Domingo-Domenech

http://www.w3.org/2001/XMLSchema#string

Marta Sanchez-Carbayo

http://www.w3.org/2001/XMLSchema#string

Mireia Castillo-Martin

http://www.w3.org/2001/XMLSchema#string

Nataliya Gladoun

http://www.w3.org/2001/XMLSchema#string

Orit Karni-Schmidt

http://www.w3.org/2001/XMLSchema#string

Scott Lowe

http://www.w3.org/2001/XMLSchema#string

Tian Huai Shen

http://www.w3.org/2001/XMLSchema#string

Yingchun Li

http://www.w3.org/2001/XMLSchema#string

P2860

p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities

Cloning and functional analysis of human p51, which structurally and functionally resembles p53

p63 Is essential for the proliferative potential of stem cells in stratified epithelia

p63 is the molecular switch for initiation of an epithelial stratification program

DeltaNp63 plays an anti-apoptotic role in ventral bladder development

Blinded by the Light: The Growing Complexity of p53

TP53 mutations in human cancers: origins, consequences, and clinical use

p63 regulates commitment to the prostate cell lineage.

Impaired p63 expression associates with poor prognosis and uroplakin III expression in invasive urothelial carcinoma of the bladder.

p53 Research: the past thirty years and the next thirty years.

P304

1350-1360

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.AJPATH.2010.11.061

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

178

http://www.w3.org/2001/XMLSchema#string

P50

Carlos Cordon-Cardo

P577

2011-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50225512

http://www.w3.org/2001/XMLSchema#string

P698

21356385

http://www.w3.org/2001/XMLSchema#string

P932

3069841

http://www.w3.org/2001/XMLSchema#string